Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.255 -2.695 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.29 Bil PE Ratio: 0 PB Ratio: 1,065.02 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 01:30PM GMT
Release Date Price: $130.51 (-0.37%)
David Neil Lebowitz;John M. Maraganore
Morgan Stanley, Research Division - VP

Good morning, and welcome to the Morgan Stanley 18th Annual Global Health Care Conference. I'm one of the biotech analysts here. My name is David Lebowitz.

Before I get going, I'm going to do the requisite disclosures.

Please note that the webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. The webcast is not for members of the press. If you are a member of the press, please disconnect, and reach out separately. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions)

I'm happy to have here, for our next session, wearing my mask for this session, is CEO John Maraganore from Alnylam. Always happy to have John here. And I guess, just to start off, if you could give us kind of the top level rundown of what's been going on with Alnylam for the last year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot